The board of directors of Kaisa Health Group Holdings Limited announced that Mr. Kwok Ying Shing has been appointed as an executive Director, the Chairman of the Board and the chairman of the nomination committee of the company, with effect from 26 February 2019. Mr. Kwok is the chairman, an executive director, the chairman of the nomination committee and a member of the remuneration committee and a substantial shareholder of Kaisa Group Holdings Ltd. He is one of the founders of Kaisa Group and was its chairman and a director since its inception in 1999. Mr. Kwok is primarily responsible for Kaisa Group's overall strategy, investment planning and human resource strategy and has extensive experience in real estate development, investment and financing management.

The Board also announced that Mr. Luo Jun, an existing executive Director, has ceased to act as the Chairman of the Board and the chairman of the Nomination Committee with effect from 26 February 2019 to align with the new arrangement of the senior management of the Company as set out in this announcement. The board further announces that Mr. Luo has been appointed as the Chief Executive Officer of the company and the Co-Vice Chairman of the Board with effect from 26 February 2019. Mr. Luo would also continue to act as an executive Director.

Mr. Luo, aged 38, was appointed as an executive Director on 2 December 2016. He has also been appointed as a director of (Zhenxing Biopharmaceutical And Chemical Co. Ltd. ("Zhenxing Biopharmaceutical)), a company incorporated in the People's Republic of China and listed on the Shenzhen Stock Exchange since 2 May 2018 and has acted as the general manager of Zhenxing Biopharmaceutical from 2 May 2018 to 17 December 2018.

Prior to this, Mr. Luo worked in Kaisa Holdings Limited, a subsidiary of Kaisa Group, a controlling shareholder of the Company. Mr. Luo also worked in and previously. Mr. Luo has extensive management experience in operational planning, commerce, hotel and healthcare industry.

Mr. Luo obtained his Bachelor Degree in Management from Nanjing University of Finance & Economics in 2003. The board announces that Mr. Wu Tianyu, an existing executive Director, has resigned as the chief executive officer (the "Chief Executive Officer") of the company with effect from 26 February 2019 to align with the new arrangement of the senior management of the company as set out in this announcement. The board further announced that Mr. Wu has been appointed as a Co-Vice Chairman of the Board with effect from 26 February 2019.

Mr. Wu would also continue to act as an executive Director. Mr. Wu, aged 54, was appointed as an executive Director on 21 May 2015 and is a member of the Remuneration Committee. Mr. Wu is currently a director of On Growth Global Development Limited and Royal Dental Laboratory Limited and the general manager of Shenzhen Jinyouran Technology Company Limited, all of which are the subsidiaries of the Company.

Mr. Wu is the spouse of Ms. Jiang Sisi, the chief operating officer of the Company. He has approximately 30 years of experience in denture profession. Mr. Wu obtained a bachelor degree in Department of Stomatology of The Fourth Military Medical University.

In his early years, Mr. Wu had developed extensive experience in stomatology and reparative surgery as a clinician in a hospital in Qingdao, the PRC for more than 7 years, during which various research articles had been pronounced by Mr. Wu in various famous professional research magazines. Mr. Wu has been the key operators of the denture business of the companies for approximately 20 years, with Mr. Wu overseeing the production of the denture products and the daily operations.